GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Shiller PE Ratio

Agios Pharmaceuticals (MEX:AGIO) Shiller PE Ratio : (As of Jun. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agios Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Agios Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Shiller PE Ratio Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agios Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Agios Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Shiller PE Ratio falls into.



Agios Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Agios Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-24.065/131.7762*131.7762
=-24.065

Current CPI (Mar. 2024) = 131.7762.

Agios Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -7.004 100.560 -9.178
201409 1.343 100.428 1.762
201412 -11.210 99.070 -14.911
201503 -1.982 99.621 -2.622
201506 -13.337 100.684 -17.456
201509 -18.081 100.392 -23.734
201512 -18.571 99.792 -24.523
201603 -10.501 100.470 -13.773
201606 -27.185 101.688 -35.229
201609 -31.517 101.861 -40.773
201612 -27.627 101.863 -35.740
201703 -29.373 102.862 -37.630
201706 -32.175 103.349 -41.025
201709 -28.855 104.136 -36.514
201712 -35.547 104.011 -45.036
201803 -29.613 105.290 -37.062
201806 -23.383 106.317 -28.982
201809 -30.489 106.507 -37.723
201812 -31.023 105.998 -38.568
201903 -30.843 107.251 -37.896
201906 -35.921 108.070 -43.801
201909 -35.733 108.329 -43.467
201912 -30.176 108.420 -36.677
202003 -13.834 108.902 -16.740
202006 -30.238 108.767 -36.635
202009 -31.590 109.815 -37.908
202012 -28.048 109.897 -33.632
202103 550.885 111.754 649.581
202106 -28.067 114.631 -32.265
202109 -32.077 115.734 -36.523
202112 -35.694 117.630 -39.987
202203 -34.645 121.301 -37.637
202206 -33.798 125.017 -35.625
202209 -29.971 125.227 -31.539
202212 13.062 125.222 13.746
202303 -26.497 127.348 -27.418
202306 -25.887 128.729 -26.500
202309 -28.567 129.860 -28.989
202312 -29.196 129.419 -29.728
202403 -24.065 131.776 -24.065

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agios Pharmaceuticals  (MEX:AGIO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Agios Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (MEX:AGIO) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals (MEX:AGIO) Headlines

From GuruFocus

Agios to Participate in March Investor Conferences

By sperokesalga sperokesalga 03-02-2023

Agios Appoints Jeffrey Capello to Board of Directors

By sperokesalga sperokesalga 04-19-2023